# LinkedIn Outreach for Medtech and Pharma

LinkedIn outreach helps medtech and pharma companies find international, product, regulatory and partnership decision-makers connected to Russia and the CIS. It works best as a precise first contact, then moves technical details and documents to email or an agreed Telegram conversation.

**Figures:** 5.93% — of contacted companies replied across our campaigns; 6,500 — clear yeses: requests for details, a proposal or a meeting

## Which medtech and pharma roles are visible on LinkedIn

LinkedIn is rarely the only working channel for a local procurement contact in Russia. It is more useful for people who work between markets: export leads, product managers, business development directors, regulatory specialists, clinical research teams and distributor managers. Their profiles often show prior roles, market responsibility and professional connections, giving you a reason to start a specific conversation.

| What you sell | Who to look for | What to check in the profile |
|---|---|---|
| Medical equipment | Business Development, Product Manager, Distributor Manager | Countries covered, dealer network experience, product launches |
| Software for clinics and laboratories | Digital Health Lead, CIO, Commercial Director | Automation projects, clinic network, laboratory focus |
| Pharma services | Regulatory Affairs, Market Access, Partnerships Lead | New-market work, registration projects, product portfolio |

Research starts with the deal path, not a job title. If your product needs a distributor, begin with the person responsible for partner networks; if it serves laboratories, look for the person responsible for that function or digital transformation. A useful list records the role, company, profile, market and reason for contact; see [B2B lead list building](/en/services/lead-list-building/).

## The first message should establish the subject in two lines

Do not send a presentation or retell your website in a LinkedIn connection request. The request earns permission for a further conversation. A relevant trigger may be expansion into new markets, a new product line, a regulatory vacancy or a stated laboratory focus; personalisation is a verifiable fact, not a compliment.

A weak opening says: “Hello, we offer an innovative solution for medical organisations. Would you be open to discussing it?” The recipient cannot see why you contacted them or what you need. A stronger opening says: “Anna, I saw that you are building a distributor network for diagnostic solutions in the CIS. We supply consumables for this channel. Could we compare which categories you are currently adding to the portfolio?” It asks one concrete question without promising savings or pressing for a meeting.

1. Send a connection request with the person’s name, company and one reason for reaching out.
2. After the connection is accepted, ask about the direction or market instead of offering a demonstration.
3. If they ask for materials, clarify the market, partnership type and the next person involved in the decision.

> Do not make medical, clinical or regulatory claims in the first message unless you can substantiate them with documentation. A LinkedIn contact begins qualification; it is not the place for advertising promises.

## Campaign pace follows profile health, not list size

LinkedIn monitors repetitive behaviour and can restrict activity. A full list of pharma companies should not be put into automation with identical invitations. A new or inactive profile needs to be established as a credible professional presence before it begins targeted outreach.

- One account should represent one clear professional profile and one audience.
- Messages should change by role: regulatory affairs and commercial leadership need different reasons to engage.
- Pauses, ignored requests or repeated declines are signals to review the segment and activity, not to make the message more generic.

No service or proxy removes the risk of losing a profile. The practical safeguard is disciplined outreach: avoid duplicate contacts, do not turn a personal profile into mass mailing, and do not approach people without context. LinkedIn should be one part of a considered [multi-channel outreach](/en/services/multichannel-outreach/) route.

## Move the conversation to the channel the decision-maker prefers

Medtech and pharma decisions often involve a long approval route. A person may accept a connection but ask for technical material by email, add a colleague, or suggest a short Telegram exchange. LinkedIn is therefore a way to identify the role and establish context, rather than an isolated funnel.

| LinkedIn signal | Next action | Why it matters |
|---|---|---|
| Accepts the connection but does not reply | Send an email with the same specific reason for contact | Give the recipient space for documents and a team response |
| Requests a presentation | Clarify the task and send a short relevant document | Avoid turning the reply into a file dump |
| Names a colleague | Research the second person’s role and continue with both | Keep procurement or regulatory input in the conversation |

Plan the connection between channels in advance: LinkedIn identifies the person and confirms their role, email carries detail, and Telegram is reserved for an agreed short exchange. Replies should be qualified by source and meaning so sales receives the product, market, role and next step, supported by [reply handling and lead qualification](/en/services/reply-handling/).

## When LinkedIn will not deliver the result you need

LinkedIn is not the right single-channel bet if you sell a standard product to local clinics and expect to reach chief physicians or procurement staff across Russia quickly. Those roles may have incomplete profiles, outdated profiles, or use LinkedIn only for hiring. It is also too early to launch if you cannot define the product, organisation type and useful action after the first conversation.

An offer without a verifiable reason will not work either. “We are looking for pharma partners” combines manufacturers, distributors, CROs, clinics and laboratories into an audience that does not exist. First define the ICP and deal path; for a narrow named-company list, [account-based marketing](/en/services/account-based-marketing/) is usually more appropriate than a flow of invitations.

- You have a segment: manufacturer, distributor, clinic, laboratory or service company.
- Each role has its own reason for a first message.
- Someone on your side can quickly answer questions about the product, documentation and partnership terms.

## Frequently asked questions

**Can LinkedIn be used to find decision-makers at Russian pharma companies?**

Yes, but the results will be incomplete. LinkedIn is especially useful for international, export, product and partnership roles; local procurement roles should be checked through additional sources.

**Should we send a presentation as soon as a connection is accepted?**

No. Start with a short question about the relevant market or direction. Send material once you know which part of it will be useful to the recipient.

**How many LinkedIn accounts does a campaign need?**

That depends on the list, the state of the available profiles and the contact scenario. Do not calculate accounts from the number of target companies alone: one profile should not represent several unrelated audiences.

**How should we respond when someone says they already have a distributor?**

Do not argue or send a general catalogue. Ask whether the category is fully covered, which markets the current arrangement serves, and who evaluates new product directions.

**Can medtech and pharma outreach run without email?**

It can, but it usually narrows the conversation. Email is better suited to documents, technical questions and bringing colleagues into an agreed discussion after the LinkedIn contact.

---
Source: https://ot9.ru/en/medtech-and-pharma/ · OT9 (KAP Group) · updated 2026-08-10